TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04928222

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin-containing MNA
Description: A 15 x 15 millimeter array containing 400 dissolvable microneedles delivering active agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-containing MNA
Description: A 15 15 x 15 millimeter array containing 400 dissolvable microneedles containing placebo
Study: NCT05724004

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT/SRS/radiation therapy
Description: Consolidation radiation therapy (SBRT/SRS/moderately hypofractionated radiation therapy)
Study: NCT04821076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: Exercise will consist of supervised resistance training, interval training and moderate intensity cycling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet intervention - Energy balance
Description: Energy balance is set to 50 kcal / kg fat-free mass

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet intervention - Energy balance
Description: Energy balance is set to 50 kcal / kg fat-free mass
Study: NCT05526677

Intervention type: DEVICE
Intervention: x-guide dynamic navigation system
Description: One implant placement is assisted with x-guide dynamic navigation system. The other implant placement is assisted with static surgical guide
Study: NCT05798975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise. 1 session of acute exercise
Description: 40 minutes on cycle ergometer, 60% of heart rate reserve

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise. 1 session of acute exercise
Description: 2 exercises for lower limbs and 2 for upper limbs with 4 sets of 12 repetitions at 60% 1-RM. 40 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no exercise
Description: Rest

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no exercise
Description: Rest
Study: NCT03425786

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic training
Description: Training in the Dix-Hallpike maneuver and the supine head roll test to diagnose BPPV.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diagnostic and treatment training
Description: Training in the Dix-Hallpike maneuver and the supine head roll test to diagnose BPPV. Training in the Epley and Barbecue maneuvers to treat BPPV.
Study: NCT06162117

Intervention type: DIAGNOSTIC_TEST
Intervention: 2- Minute Step Test
Description: 2- Minute Step Test will be administered to patients with traumatic meniscus tear
Study: NCT05392556

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Cerebiome (Lallemand Health Solutions): probiotic supplement containing Bifidobacterium longum R0175, Lactobacillus helveticus R0052, and maltodextrin. Dosing: Oral, 3.6 g/d containing 3x10\^9 CFU/d (powder form)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: Bimuno-GOS (Clasado Biosciences): Dosing: Oral; 3.6 g/d containing 2.75 g active GOS/d (powder form)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin 3.6 g/d (powder form)
Study: NCT06469047

Intervention type: DIAGNOSTIC_TEST
Intervention: Enzyme-linked immunosorbent assay
Description: Serum N/OFQ , IL-1β and NE levels were detected.

Intervention type: DIAGNOSTIC_TEST
Intervention: Enzyme-linked immunosorbent assay
Description: Serum N/OFQ , IL-1β and NE levels were detected.

Intervention type: DIAGNOSTIC_TEST
Intervention: Enzyme-linked immunosorbent assay
Description: Serum N/OFQ , IL-1β and NE levels were detected.

Intervention type: DIAGNOSTIC_TEST
Intervention: Enzyme-linked immunosorbent assay
Description: Serum N/OFQ , IL-1β and NE levels were detected.
Study: NCT02718105

Intervention type: GENETIC
Intervention: KIR HLAC determinations
Description: We will take blood samples for KIR HLA-C determinations.
Study: NCT06014112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freestyle Libre Pro iQ
Description: Freestyle Libre Pro iQ is a professional sensor, marketed by the Abbott laboratory, for continuous, non-invasive interstitial glucose measurement allowing the recording of glycemic parameters for 2 weeks.~The study will be offered to any subject with an ACS. The installation of the Freestyle Libre Pro iQ sensor will be performed upon admission to intensive care Cardiology and left in place for the duration of hospitalization. In case of the Freestyle Libre Pro iQ sensor defective or removed before discharge from hospital, and if the patient tolerates it, a new the Freestyle Libre Pro iQ sensor will be placed. If the duration of hospitalization exceeds 14 days, a 2nd sensor will be placed.
Study: NCT05514834

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellular Matrix TM BCT-HA Kit (ref. BCT-HA-3)
Description: Injections with platelet-rich plasma and hyaluronic acid

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PRP Only
Description: platelet rich plasma without hyaluronic acid

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Neither PRP nor hyaluronic acid
Study: NCT05499676

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SilverCloud Health Mobile Intervention
Description: SilverCloud Health is a mobile mental health platform offering cognitive-behavioral therapy-based guided self-help programs, including one for anorexia nervosa developed by our team. Participants in this arm will receive the support of a coach to guide them through the program. Participants will be able to communicate with their coach within the program.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SilverCloud Health Mobile Intervention
Description: SilverCloud Health is a mobile mental health platform offering cognitive-behavioral therapy-based guided self-help programs, including one for anorexia nervosa developed by our team. Participants in this arm will receive the support of a coach to guide them through the program. Participants will be able to communicate with their coach within the program.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Social Networking Intervention: Facebook
Description: Facebook is a social networking site that will offer participants the opportunity to interact with study team posts, post themselves, and connect with others in the study experiencing similar struggles in a private group
Study: NCT06529328

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: core stability
Description: In this study the experimental group will perform core stability exercises 3 times per week for an 8-week period and each session of 30 to 45 minutes, the core stability exercises will work on abdominals and trunk muscles with challenges.Subjects received 25 min conventional therapy in addition to 30 30-minute trunk stabilization exercise program conducted for 3 days\\week on non-consecutive days.~Passive stretching exercises are applied to all tight muscles, including the hamstrings and calf muscles in the lower limb. It is performed five times initially, building up to ten repetitions, stretching for 5 times, and then allowing relaxation for 5time. Strengthening exercises for back, hip, and knee extensor muscles (for 10 minutes).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: core stability
Description: In this study the experimental group will perform core stability exercises 3 times per week for an 8-week period and each session of 30 to 45 minutes, the core stability exercises will work on abdominals and trunk muscles with challenges.Subjects received 25 min conventional therapy in addition to 30 30-minute trunk stabilization exercise program conducted for 3 days\\week on non-consecutive days.~Passive stretching exercises are applied to all tight muscles, including the hamstrings and calf muscles in the lower limb. It is performed five times initially, building up to ten repetitions, stretching for 5 times, and then allowing relaxation for 5time. Strengthening exercises for back, hip, and knee extensor muscles (for 10 minutes).
Study: NCT06166953

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: digital technology-supported education
Description: The education will include information about surgical process and care after surgery.
Study: NCT06161038

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LASER
Description: LLLT with a 685-nm wavelength and an output of 30 mW (BTL-5000 Laser, BTL, Stevenage, UK) at energy densities of 8 J/cm2 at trigger point of upper trapezius muscle.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LASER
Description: LLLT with a 685-nm wavelength and an output of 30 mW (BTL-5000 Laser, BTL, Stevenage, UK) at energy densities of 8 J/cm2 at trigger point of upper trapezius muscle.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: 1 MHz therapeutic ultrasound for 5 min at a frequency of 4-6 times two week at the painful upper trapezius muscle.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: 1 MHz therapeutic ultrasound for 5 min at a frequency of 4-6 times two week at the painful upper trapezius muscle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolotherapy
Description: Hypertonic prolotherapy at perimysium of upper trapezius muscle. The injectant is 5ml 5% dextrose solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolotherapy
Description: Hypertonic prolotherapy at perimysium of upper trapezius muscle. The injectant is 5ml 5% dextrose solution.
Study: NCT05992285

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: the intensity of stimulus was 80% Resting motor threshold(RMT); the frequency of trains was 50 Hz and the number of pulses was three; and the frequency of intertrain intervals was 5 Hz and pulses number was 200. Two groups were repeatedly stimulated in the dentate nucleus of bilateral cerebellum, the interval of each group was 5min, and the number of stimulation pulses at each site was 1200.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: the intensity of stimulus was 80% Resting motor threshold(RMT); the frequency of trains was 50 Hz and the number of pulses was three; and the frequency of intertrain intervals was 5 Hz and pulses number was 200. Two groups were repeatedly stimulated in the dentate nucleus of bilateral cerebellum, the interval of each group was 5min, and the number of stimulation pulses at each site was 1200.
Study: NCT05610813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VER-01
Description: Standardized oleoresin of Cannabis sativa L. folium cum flore, THC-chemotype (cannabis leaves and - flowers), corresponding to 21 mg (-)-trans-Δ9-Tetra-hydrocannabinol (THC) per gram drug product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid therapy
Description: The patient-specific selection of the marketed opioid (based on standard of care and provided for this study) is at the discretion of the investigator and made at Visit 1, i.e., before randomization at Visit 2.
Study: NCT06402513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravagalimab
Description: Subcutaneous Injection
Study: NCT03895827

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Initiation and Management after Overdose (RIMO)
Description: RIMO uses motivational interviewing and linkage assistance techniques to get people who have had a recent opioid overdose reversal to go to medication-assisted treatment (MAT), stay in MAT, and, if they drop out, go back to MAT treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive Referral to Treatment Control
Description: Currently neither first responders or emergency department staff regularly refer people to any kind of substance use after an opioid overdose reversal. In the passive referral condition they will at least get a brochure with information on recently expanded and publicly-funded medication-assisted treatment in their community.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Referral to Treatment Control
Description: Currently neither first responders or emergency department staff regularly refer people to any kind of substance use after an opioid overdose reversal. In the passive referral condition they will at least get a brochure with information on recently expanded and publicly-funded medication-assisted treatment in their community.
Study: NCT06489301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractionated Laser Resurfacing
Description: A rejuvenating laser that makes tiny holes in the very superficial part of the skin.
Study: NCT05120219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC tablet
Description: single HR20033 FDC tablet fed, take orally on an empty stomach and then after meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC tablet
Description: single HR20033 FDC tablet fasted, take orally after meals and then on an empty stomach

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC tablet
Description: single and multiple doses of HR20033 FDC tablet
Study: NCT05397379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC96719
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC96719
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC96719
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC96719
Description: Oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparator
Study: NCT05181709

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Description: Administered intranasal (IN) and intramuscular (IM) in combination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NDV-HXP-S IN low dose
Description: Allantoic fluid diluted in Phosphate buffered saline (PBS), to be further diluted to dose strength in sodium chloride.~Strength: 3.3x108\^8 EID50.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NDV-HXP-S IN low dose
Description: Allantoic fluid diluted in Phosphate buffered saline (PBS), to be further diluted to dose strength in sodium chloride.~Strength: 3.3x108\^8 EID50.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NDV-HXP-S IM low dose
Description: Allantoic fluid diluted in Phosphate buffered saline (PBS), to be further diluted to dose strength in sodium chloride.~Strength: 3.3x10\^8 EID50.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NDV-HXP-S IM low dose
Description: Allantoic fluid diluted in Phosphate buffered saline (PBS), to be further diluted to dose strength in sodium chloride.~Strength: 3.3x10\^8 EID50.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NDV-HXP-S IN high dose
Description: Allantoic fluid diluted in Phosphate buffered saline (PBS). Strength: 1x10\^9 EID50.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NDV-HXP-S IN high dose
Description: Allantoic fluid diluted in Phosphate buffered saline (PBS). Strength: 1x10\^9 EID50.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NDV-HXP-S IM high dose
Description: Allantoic fluid diluted in Phosphate buffered saline (PBS). Strength: 1x10\^9 EID50.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NDV-HXP-S IM high dose
Description: Allantoic fluid diluted in Phosphate buffered saline (PBS). Strength: 1x10\^9 EID50.
Study: NCT06251700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENDO-AID CADe
Description: ENDO-AID CADe will be used during the withdrawal process of the colonscopy
Study: NCT06442267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin Injectable Solution
Description: Subcutaneous Enoxaparin will be dosed at 0.5 mg/kg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argatroban, 1 Mg/mL Intravenous Solution
Description: Intravenous Argatroban will be administered as a continuous infusion of 0.1-1 µg/kg/min with a target modified thrombin time measured using Hemoclot of 0,40 - 0,60 µg/mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Description: Unfractionated heparin will be administered as a continuous infusion of 7.5-20 units/kg/h with a target Anti FXa calibrated for UFH of 0.3-0.5 u/mL.
Study: NCT05580913

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: 12 weeks of resistance-training performed two times per week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: 12 weeks of resistance-training performed two times per week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training
Description: 12 weeks of resistance-training performed two times per week
Study: NCT05669092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 3mg/Kg iv d1q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 3mg/Kg iv d1q2w

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CRT
Description: IMRT 50Gy/25fx 625mg/m2 bid d1-5 qw Irinotecan:1、Full wild (GG+6/6): 80mg/m2/week for 5 times 2、Single site mutation (GG+6/7 or GA+6/6): 65mg/m2/week for 5 times 3、Double locus mutation (GG+7/7 or AA+6/6 or GA+6/7): 50mg/m2/week for the 1st, 2nd, 4th and 5th week for 4 times

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CRT
Description: IMRT 50Gy/25fx 625mg/m2 bid d1-5 qw Irinotecan:1、Full wild (GG+6/6): 80mg/m2/week for 5 times 2、Single site mutation (GG+6/7 or GA+6/6): 65mg/m2/week for 5 times 3、Double locus mutation (GG+7/7 or AA+6/6 or GA+6/7): 50mg/m2/week for the 1st, 2nd, 4th and 5th week for 4 times

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SCRT
Description: 25Gy/5fx

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELIRI
Description: Capecitabine: 1000mg/m2 bid d1-14 Irinotecan: 200mg/m2 ivgtt d1 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFRINOX
Description: Irinotecan: 150mg/m2 ivgtt d1 (double locus mutation downregulated to 120mg/m2) Oxaliplatin: 85mg/m2 ivgtt d1 5-FU: 2400mg/m2 ivgtt 46h q2w
Study: NCT06271551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen
Description: Participants (n=155) receiving transdermal estradiol for 12 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Androgen deprivation therapy
Description: Participants (n=155) receiving solely androgen deprivation therapy for 12 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training
Description: Participants (n=30 in each arm) performing supervised resistance training for six months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Participants (n=30 in each arm) performing supervised resistance training for six months.
Study: NCT05779566

Intervention type: DIAGNOSTIC_TEST
Intervention: bone densitometry
Description: bone densitometry every 6 month

Intervention type: DIAGNOSTIC_TEST
Intervention: bone densitometry
Description: bone densitometry every 6 month
Study: NCT05850871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAZ/AVI plus Aztreonam
Description: Samples of the patients will be examined such as the routine blood test, blood culture et al.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Conventional treatment
Study: NCT05114356

Intervention type: DEVICE
Intervention: TIDAL Cervical Interbody Fusion implant
Description: Cervical interbody fusion device
Study: NCT05728112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrogen Inhalation
Description: The manufacturer will install a hydrogen inhalation machine (hydrogen inhalation or air inhalation) at the subject's home and explain the relevant operation methods. The research executor will pay attention to the LINE group on the first day of installation, and obtain the pre-test basic value data through the google form After (baseline data), continuous hydrogen inhalation was performed daily, and four post-test evaluations were performed before the inhalation and on the 1st, 3rd, 7th, and 14th days after the inhalation was started.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ordinary Air Inhalation
Description: The control group was inhaled with the same machine as the experimental group, but the gas was only ordinary air, which was used as a placebo control.
Study: NCT05349448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hylase plus Triamcinolone plus sterile isotonic saline
Description: transforaminal fluroscopic epidural injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hylase plus Dexmedetomidine plus Triamcinolone
Description: transforaminal fluroscopic epidural injection
Study: NCT06193434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI356 for MAD
Description: Receive IBI356 in a multiple dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab for MAD
Description: Active comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI356 for SAD
Description: Receive IBI356 in a single dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for SAD
Description: Receive placebo in a single dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MAD
Description: Receive placebo in a multiple dose.
Study: NCT05035069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofol
Description: Ciprofol infusion, starting with 0.8 \~ 1mg/kg/h until BIS value below 60 (including 60), and then 0.2 \~ 0.6mg/kg/h until the end of the operation, ciprofol infusion was adjusted to keep the BIS value between 40-60.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol infusion, starting with 4 \~ 5mg/kg/h until BIS value below 60 (including 60), and then 1 \~ 3mg/kg/h until the end of the operation, propofol infusion was adjusted to keep the BIS value between 40-60.
Study: NCT03292822

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Licochalcone A
Description: Licochalcone A is a chalconoid, a type of natural phenols. It can be isolated from root of Glycyrrhiza glabra (liquorice) or Glycyrrhiza inflata. It shows antimalarial, anticancer, antibacterial and antiviral (specifically against influenza neuraminidase) properties in vitro.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: chemotherapeutic drug
Study: NCT05941039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestibular training using VR followed by Control
Description: A cross-over design will be used with group one receiving the training intervention for 6 days, a 4-day washout period, and a 6-day no-training period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control followed by Vestibular training using VR
Description: Group two will follow the reverse sequence.